The content on this site is intended for healthcare professionals only
Dr Dalgleish talks to ecancertv at the 1st Immunotherapy of Cancer Conference ( ITOC ) in Munich about combining chemotherapy and immunotherapy.
Chemotherapy and Immunotherapy were always considered incompatible in the treatment of cancer. However, analysis of sequential use has revealed that there may be significant additive - if not synergistic - potential, in enhancing the immune response to cancer.
There are many reasons why chemotherapy may enhance immune therapy. These include 1) the release of tumour antigens to a primed immune response, 2) the suppression and reduction of suppressor and regulatory T cells in the tumour and stromal tissues, 3) The priming of tumour cells to make them more visible to the immune response, 4) reduction of inflammatory and growth factor drive.
Enhancing the immune response prior to chemotherapy and releasing antigens as well as stimulating the immune response after chemotherapy or radiotherapy are both effective models.
There is a good case to prime with non-specific vaccine activators, to then treat with chemotherapy followed by check point inhibitors and then low dose cytokines.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Choosing 1st line TKI Wisely in patients with CML
Multiple myeloma In Rwanda: The need for further research
